Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis

Experimental Hematology

Volumn 43, Issue 8, 2015, Pages 609-624

  Eriksson, Anna ^a   Lennartsson, Andreas ^b   Lehmann, Sören ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; COHESIN; DECITABINE; TUMOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ASXL1 GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMATIN CONDENSATION; CHROMOSOME ABERRATION; DNA METHYLATION; DNMT3A GENE; DRUG TARGETING; EPIGENETICS; EZH2 GENE; GENE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENE FUSION; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC MARKER; HISTONE MODIFICATION; HUMAN; LEUKEMOGENESIS; MLL GENE; MUTATIONAL ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PRELEUKEMIA; PRIORITY JOURNAL; REVIEW; TET2 GENE; ANIMAL; CELL TRANSFORMATION; CHROMOSOME; GENETIC EPIGENESIS; GENETICS; METABOLISM; MORTALITY; PATHOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOMES, MAMMALIAN; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM PROTEINS;

EID: 84938864666     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2015.05.009     Document Type: Review

References (206)

1. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon. 4th ed.
2. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368:2059-2074. Cancer Genome Atlas Research Network.
3. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
4. Marcucci G., Haferlach T., Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011, 29:475-486.
5. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458.
6. Kelly L.M., Gilliland D.G. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002, 3:179-198.
7. Shih A.H., Abdel-Wahab O., Patel J.P., Levine R.L. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012, 12:599-612.
8. Abdel-Wahab O., Levine R.L. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013, 121:3563-3572.
9. Mehdipour P., Santoro F., Minucci S. Epigenetic alterations in acute myeloid leukemias. FEBS J 2015, 282:1786-1800.
10. Burnett A., Wetzler M., Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011, 29:487-494.
11. Juliusson G., Antunovic P., Derolf A., et al. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113:4179-4187.
12. Griffiths E.A., Gore S.D. Epigenetic therapies in MDS and AML. Adv Exp Med Biol 2013, 754:253-283.
13. Doi A., Park I.H., Wen B., et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009, 41:1350-1353.
14. Irizarry R.A., Ladd-Acosta C., Wen B., et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009, 41:178-186.
15. Ronnerblad M., Andersson R., Olofsson T., et al. Analysis of the DNA methylome and transcriptome in granulopoiesis reveals timed changes and dynamic enhancer methylation. Blood 2014, 123:e79-e89.
16. Schmidl C., Klug M., Boeld T.J., et al. Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res 2009, 19:1165-1174.
17. Suzuki M.M., Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008, 9:465-476.
18. Jones P.A., Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 2009, 10:805-811.
19. Challen G.A., Sun D., Jeong M., et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012, 44:23-31.
20. Challen G.A., Sun D., Mayle A., et al. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell 2014, 15:350-364.
21. Prasad P., Ronnerblad M., Arner E., et al. High-throughput transcription profiling identifies putative epigenetic regulators of hematopoiesis. Blood 2014, 123:e46-e57.
22. Bhutani N., Brady J.J., Damian M., Sacco A., Corbel S.Y., Blau H.M. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 2010, 463:1042-1047.
23. Cortazar D., Kunz C., Selfridge J., et al. Embryonic lethal phenotype reveals a function of TDG in maintaining epigenetic stability. Nature 2011, 470:419-423.
24. Cortellino S., Xu J., Sannai M., et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011, 146:67-79.
25. Inoue A., Zhang Y. Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. Science 2011, 334:194.
26. Iqbal K., Jin S.G., Pfeifer G.P., Szabo P.E. Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proc Natl Acad Sci U S A 2011, 108:3642-3647.
27. Rasmussen K.D., Jia G., Johansen J.V., et al. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev 2015, 29:910-922.
28. Talbert P.B., Henikoff S. Histone variants-Ancient wrap artists of the epigenome. Nat Rev Mol Cell Biol 2010, 11:264-275.
29. Van Hooser A.A., Ouspenski, Gregson H.C., et al. Specification of kinetochore-forming chromatin by the histone H3 variant CENP-A. J Cell Sci 2001, 114(Pt 19):3529-3542.
30. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011, 21:381-395.
31. Chow J., Heard E. X inactivation and the complexities of silencing a sex chromosome. Curr Opin Cell Biol 2009, 21:359-366.
32. Van Attikum H., Gasser S.M. Crosstalk between histone modifications during the DNA damage response. Trends Cell Biol 2009, 19:207-217.
33. Zhu Q., Wani A.A. Histone modifications: Crucial elements for damage response and chromatin restoration. J Cell Physiol 2010, 223:283-288.
34. Ernst J., Kheradpour P., Mikkelsen T.S., et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011, 473:43-49.
35. Azuara V., Perry P., Sauer S., et al. Chromatin signatures of pluripotent cell lines. Nat Cell Biol 2006, 8:532-538.
36. Bernstein B.E., Mikkelsen T.S., Xie X., et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125:315-326.
37. Mikkelsen T.S., Ku M., Jaffe D.B., et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 2007, 448:553-560.
38. Cui K., Zang C., Roh T.Y., et al. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell 2009, 4:80-93.
39. Barski A., Cuddapah S., Cui K., et al. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129:823-837.
40. Roh T.Y., Cuddapah S., Cui K., Zhao K. The genomic landscape of histone modifications in human T cells. Proc Natl Acad Sci U S A 2006, 103:15782-15787.
41. Andersson R., Gebhard C., Miguel-Escalada I., et al. An atlas of active enhancers across human cell types and tissues. Nature 2014, 507:455-461.
42. Score J., Hidalgo-Curtis C., Jones A.V., et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2012, 119:1208-1213.
43. Morin R.D., Johnson N.A., Severson T.M., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42:181-185.
44. Nikoloski G., Langemeijer S.M., Kuiper R.P., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010, 42:665-667.
45. Clapier C.R., Cairns B.R. The biology of chromatin remodeling complexes. Annu Rev Biochem 2009, 78:273-304.
46. Burgess R.J., Zhang Z. Histone chaperones in nucleosome assembly and human disease. Nat Struct Mol Biol 2013, 20:14-22.
47. Valouev A., Johnson S.M., Boyd S.D., et al. Determinants of nucleosome organization in primary human cells. Nature 2011, 474:516-520.
48. Prasad P., Lennartsson A., Ekwall K. The roles of SNF2/SWI2 nucleosome remodeling enzymes in blood cell differentiation and leukemia. Biomed Res Int 2015, 2015:347571.
49. Zilberman D., Coleman-Derr D., Ballinger T., Henikoff S. Histone H2A.Z and DNA methylation are mutually antagonistic chromatin marks. Nature 2008, 456:125-129.
50. Coleman-Derr D., Zilberman D. DNA methylation, H2A.Z, and the regulation of constitutive expression. Cold Spring Harb Symp Quant Biol 2012, 77:147-154.
51. Hashimoto H., Vertino P.M., Cheng X. Molecular coupling of DNA methylation and histone methylation. Epigenomics 2010, 2:657-669.
52. Ansari K.I., Mandal S.S. Mixed lineage leukemia: Roles in gene expression, hormone signaling and mRNA processing. FEBS J 2010, 277:1790-1804.
53. Birke M., Schreiner S., Garcia-Cuellar M.P., Mahr K., Titgemeyer F., Slany R.K. The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. Nucleic Acids Res 2002, 30:958-965.
54. Cierpicki T., Risner L.E., Grembecka J., et al. Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia. Nat Struct Mol Biol 2010, 17:62-68.
55. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4:143-153.
56. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009, 1:239-259.
57. Wild L., Flanagan J.M. Genome-wide hypomethylation in cancer may be a passive consequence of transformation. Biochim Biophys Acta 2010, 1806:50-57.
58. Shao C., Lacey M., Dubeau L., Ehrlich M. Hemimethylation footprints of DNA demethylation in cancer. Epigenetics 2009, 4:165-175.
59. Hansen K.D., Timp W., Bravo H.C., et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011, 43:768-775.
60. Agrawal S., Hofmann W.K., Tidow N., et al. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 2007, 109:3895-3905.
61. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003, 17:1813-1819.
62. Issa J.P., Zehnbauer B.A., Kaufmann S.H., Biel M.A., Baylin S.B. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 1997, 57:1678-1681.
63. Melki J.R., Vincent P.C., Clark S.J. Cancer-specific region of hypermethylation identified within the HIC1 putative tumour suppressor gene in acute myeloid leukaemia. Leukemia 1999, 13:877-883.
64. Plass C., Yu F., Yu L., et al. Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia: Involvement of the WIT-1 gene. Oncogene 1999, 18:3159-3165.
65. Teofili L., Martini M., Luongo M., et al. Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia 2003, 17:919-924.
66. Tessema M., Langer F., Dingemann J., Ganser A., Kreipe H., Lehmann U. Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia 2003, 17:910-918.
67. Toyota M., Kopecky K.J., Toyota M.O., Jair K.W., Willman C.L., Issa J.P. Methylation profiling in acute myeloid leukemia. Blood 2001, 97:2823-2829.
68. Gronbaek K., Muller-Tidow C., Perini G., et al. A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies. Haematologica 2012, 97:1380-1388.
69. Bocker M.T., Hellwig I., Breiling A., Eckstein V., Ho A.D., Lyko F. Genome-wide promoter DNA methylation dynamics of human hematopoietic progenitor cells during differentiation and aging. Blood 2011, 117:e182-e189.
70. Ji H., Ehrlich L.I., Seita J., et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010, 467:338-342.
71. Pronier E., Almire C., Mokrani H., et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011, 118:2551-2555.
72. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
73. Garcia-Manero G. Introduction: advances in myelodysplastic syndromes. Semin Oncol 2011, 38:612.
74. Qu Y., Lennartsson A., Gaidzik V.I., et al. Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes. Epigenetics 2014, 9:1108-1119.
75. Alvarez S., Suela J., Valencia A., et al. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One 2010, 5:e12197.
76. Bullinger L., Ehrich M., Dohner K., et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010, 115:636-642.
77. Deneberg S., Guardiola P., Lennartsson A., et al. Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood 2011, 118:5573-5582.
78. Figueroa M.E., Lugthart S., Li Y., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13-27.
79. Wilop S., Fernandez A.F., Jost E., et al. Array-based DNA methylation profiling in acute myeloid leukaemia. Br J Haematol 2011, 155:65-72.
80. Di Croce L., Raker V.A., Corsaro M., et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002, 295:1079-1082.
81. Liu S., Shen T., Huynh L., et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 2005, 65:1277-1284.
82. Schoofs T., Rohde C., Hebestreit K., et al. DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding. Blood 2013, 121:178-187.
83. Thurman R.E., Rynes E., Humbert R., et al. The accessible chromatin landscape of the human genome. Nature 2012, 489:75-82.
84. Stadler M.B., Murr R., Burger L., et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature 2011, 480:490-495.
85. Timp W., Feinberg A.P. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 2013, 13:497-510.
86. Chim C.S., Tam C.Y., Liang R., Kwong Y.L. Methylation of p15 and p16 genes in adult acute leukemia: Lack of prognostic significance. Cancer 2001, 91:2222-2229.
87. Kroeger H., Jelinek J., Estecio M.R., et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 2008, 112:1366-1373.
88. Matsushita C., Yang Y., Takeuchi S., et al. Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia. Oncol Rep 2004, 12:97-99.
89. Olesen L.H., Aggerholm A., Andersen B.L., et al. Molecular typing of adult acute myeloid leukaemia: Significance of translocations, tandem duplications, methylation, and selective gene expression profiling. Br J Haematol 2005, 131:457-467.
90. Chim C.S., Liang R., Tam C.Y., Kwong Y.L. Methylation of p15 and p16 genes in acute promyelocytic leukemia: Potential diagnostic and prognostic significance. J Clin Oncol 2001, 19:2033-2040.
91. Wong I.H., Ng M.H., Huang D.P., Lee J.C. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: Potential prognostic implications. Blood 2000, 95:1942-1949.
92. Deneberg S., Grovdal M., Karimi M., et al. Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia 2010, 24:932-941.
93. Marcucci G., Yan P., Maharry K., et al. Epigenetics meets genetics in acute myeloid leukemia: Clinical impact of a novel seven-gene score. J Clin Oncol 2014, 32:548-556.
94. Bartholdy B., Christopeit M., Will B., et al. HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. J Clin Invest 2014, 124:1158-1167.
95. Conway O'Brien E., Prideaux S., Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol 2014, 2014:103175.
96. Gutierrez S.E., Romero-Oliva F.A. Epigenetic changes: A common theme in acute myelogenous leukemogenesis. J Hematol Oncol 2013, 6:57.
97. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007, 7:823-833.
98. Di Croce L. Chromatin modifying activity of leukaemia associated fusion proteins. Hum Mol Genet 2005, 14(Spec No 1):R77-R84.
99. Wang G.G., Allis C.D., Chi P. Chromatin remodeling and cancer: part I. Covalent histone modifications. Trends Mol Med 2007, 13:363-372.
100. You J.S., Jones P.A. Cancer genetics and epigenetics: two sides of the same coin?. Cancer Cell 2012, 22:9-20.
101. Amann J.M., Nip J., Strom D.K., et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 2001, 21:6470-6483.
102. Grignani F., De Matteis S., Nervi C., et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998, 391:815-818.
103. Hoemme C., Peerzada A., Behre G., et al. Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood 2008, 111:2887-2895.
104. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6:38-51.
105. Villa R., Pasini D., Gutierrez A., et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 2007, 11:513-525.
106. Figueroa M.E., Reimers M., Thompson R.F., et al. An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One 2008, 3:e1882.
107. Muller-Tidow C., Klein H.U., Hascher A., et al. Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood 2010, 116:3564-3571.
108. Holz-Schietinger C., Matje D.M., Harrison M.F., Reich N.O. Oligomerization of DNMT3A controls the mechanism of de novo DNA methylation. J Biol Chem 2011, 286:41479-41488.
109. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
110. Jeong M., Sun D., Luo M., et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat Genet 2014, 46:17-23.
111. Xie W., Schultz M.D., Lister R., et al. Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell 2013, 153:1134-1148.
112. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363:2424-2433.
113. Yamashita Y., Yuan J., Suetake I., et al. Array-based genomic resequencing of human leukemia. Oncogene 2010, 29:3723-3731.
114. Yan X.J., Xu J., Gu Z.H., et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011, 43:309-315.
115. Marcucci G., Metzeler K.H., Schwind S., et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012, 30:742-750.
116. Thiede C. Mutant DNMT3A: teaming up to transform. Blood 2012, 119:5615-5617.
117. Kim S.J., Zhao H., Hardikar S., Singh A.K., Goodell M.A., Chen T. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 2013, 122:4086-4089.
118. Cerami E., Gao J., Dogrusoz U., et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012, 2:401-404.
119. Patel J.P., Gonen M., Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089.
120. Ribeiro A.F., Pratcorona M., Erpelinck-Verschueren C., et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood 2012, 119:5824-5831.
121. Thol F., Damm F., Ludeking A., et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011, 29:2889-2896.
122. Genovese G., Kahler A.K., Handsaker R.E., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014, 371:2477-2487.
123. Jaiswal S., Fontanillas P., Flannick J., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014, 371:2488-2498.
124. Xie M., Lu C., Wang J., et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014, 20:1472-1478.
125. Falini B., Sportoletti P., Brunetti L., Martelli M.P. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics. Br J Haematol 2015, 170:305-322.
126. Figueroa M.E., Abdel-Wahab O., Lu C., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
127. DeBerardinis R.J., Mancuso A., Daikhin E., et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007, 104:19345-19350.
128. Amary M.F., Bacsi K., Maggiani F., et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011, 224:334-343.
129. Borger D.R., Tanabe K.K., Fan K.C., et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012, 17:72-79.
130. Cairns R.A., Iqbal J., Lemonnier F., et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012, 119:1901-1903.
131. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058-1066.
132. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.
133. Abbas S., Lugthart S., Kavelaars F.G., et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 2010, 116:2122-2126.
134. Boissel N., Nibourel O., Renneville A., et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2010, 28:3717-3723.
135. Marcucci G., Maharry K., Wu Y.Z., et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28:2348-2355.
136. Paschka P., Schlenk R.F., Gaidzik V.I., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28:3636-3643.
137. Patnaik M.M., Hanson C.A., Hodnefield J.M., et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 2012, 26:101-105.
138. Rakheja D., Konoplev S., Medeiros L.J., Chen W. IDH mutations in acute myeloid leukemia. Hum Pathol 2012, 43:1541-1551.
139. Tefferi A., Lasho T.L., Abdel-Wahab O., et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010, 24:1302-1309.
140. Green C.L., Evans C.M., Hills R.K., Burnett A.K., Linch D.C., Gale R.E. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010, 116:2779-2782.
141. Koszarska M., Bors A., Feczko A., et al. Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. Leuk Lymphoma 2013, 54:1028-1035.
142. Ward P.S., Patel J., Wise D.R., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
143. Dang L., White D.W., Gross S., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
144. Gross S., Cairns R.A., Minden M.D., et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010, 207:339-344.
145. Schnittger S., Haferlach C., Ulke M., Alpermann T., Kern W., Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010, 116:5486-5496.
146. Chowdhury R., Yeoh K.K., Tian Y.M., et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011, 12:463-469.
147. Esteve P.O., Chin H.G., Smallwood A., et al. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev 2006, 20:3089-3103.
148. Xu W., Yang H., Liu Y., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
149. Zhao S., Lin Y., Xu W., et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324:261-265.
150. Im A.P., Sehgal A.R., Carroll M.P., et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014, 28:1774-1783.
151. Abdel-Wahab O., Mullally A., Hedvat C., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147.
152. Hackett J.A., Sengupta R., Zylicz J.J., et al. Germline DNA demethylation dynamics and imprint erasure through 5-hydroxymethylcytosine. Science 2013, 339:448-452.
153. He Y.F., Li B.Z., Li Z., et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333:1303-1307.
154. Ito S., D'Alessio A.C., Taranova O.V., Hong K., Sowers L.C., Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466:1129-1133.
155. Jankowska A.M., Szpurka H., Tiu R.V., et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009, 113:6403-6410.
156. Ono R., Taki T., Taketani T., Taniwaki M., Kobayashi H., Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 2002, 62:4075-4080.
157. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
158. Tefferi A., Levine R.L., Lim K.H., et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, 23:900-904.
159. Kosmider O., Gelsi-Boyer V., Ciudad M., et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009, 94:1676-1681.
160. Abdel-Wahab O., Manshouri T., Patel J., et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010, 70:447-452.
161. Metzeler K.H., Maharry K., Radmacher M.D., et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011, 29:1373-1381.
162. Weissmann S., Alpermann T., Grossmann V., et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 2012, 26:934-942.
163. Gaidzik V.I., Paschka P., Spath D., et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 2012, 30:1350-1357.
164. Langemeijer S.M., Kuiper R.P., Berends M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41:838-842.
165. Nibourel O., Kosmider O., Cheok M., et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010, 116:1132-1135.
166. Ko M., Huang Y., Jankowska A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
167. Moran-Crusio K., Reavie L., Shih A., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20:11-24.
168. Abdel-Wahab O., Adli M., LaFave L.M., et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012, 22:180-193.
169. Gelsi-Boyer V., Brecqueville M., Devillier R., Murati A., Mozziconacci M.J., Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012, 5:12.
170. Fisher C.L., Lee I., Bloyer S., et al. Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. Dev Biol 2010, 337:9-15.
171. Boultwood J., Perry J., Pellagatti A., et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010, 24:1062-1065.
172. Chou W.C., Chou S.C., Liu C.Y., et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011, 118:3803-3810.
173. Chou W.C., Hou H.A., Chen C.Y., et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010, 115:2749-2754.
174. Schnittger S., Eder C., Jeromin S., et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013, 27:82-91.
175. Margueron R., Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349.
176. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003, 22:5323-5335.
177. Su I.H., Basavaraj A., Krutchinsky A.N., et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol 2003, 4:124-131.
178. Herrera-Merchan A., Arranz L., Ligos J.M., de Molina A., Dominguez O., Gonzalez S. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun 2012, 3:623.
179. Lessard J., Schumacher A., Thorsteinsdottir U., van Lohuizen M., Magnuson T., Sauvageau G. Functional antagonism of the polycomb-group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev 1999, 13:2691-2703.
180. Ernst T., Chase A.J., Score J., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010, 42:722-726.
181. Wang X., Dai H., Wang Q., et al. EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia. PLoS One 2013, 8:e61341.
182. Dohner K., Tobis K., Ulrich R., et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002, 20:3254-3261.
183. Cosgrove M.S., Patel A. Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. FEBS J 2010, 277:1832-1842.
184. Milne T.A., Briggs S.D., Brock H.W., et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002, 10:1107-1117.
185. Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol 2011, 152:141-154.
186. DiMartino J.F., Ayton P.M., Chen E.H., Naftzger C.C., Young B.D., Cleary M.L. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood 2002, 99:3780-3785.
187. Dobson C.L., Warren A.J., Pannell R., et al. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J 1999, 18:3564-3574.
188. Lavau C., Du C., Thirman M., Zeleznik-Le N. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J 2000, 19:4655-4664.
189. Okada Y., Feng Q., Lin Y., et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
190. Chang M.J., Wu H., Achille N.J., et al. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res 2010, 70:10234-10242.
191. Nguyen A.T., Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev 2011, 25:1345-1358.
192. Daigle S.R., Olhava E.J., Therkelsen C.A., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011, 20:53-65.
193. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
194. Sexton T., Schober H., Fraser P., Gasser S.M. Gene regulation through nuclear organization. Nat Struct Mol Biol 2007, 14:1049-1055.
195. Berman B.P., Weisenberger D.J., Aman J.F., et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet 2012, 44:40-46.
196. Coolen M.W., Stirzaker C., Song J.Z., et al. Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol 2010, 12:235-246.
197. Weber M., Davies J.J., Wittig D., et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005, 37:853-862.
198. Guelen L., Pagie L., Brasset E., et al. Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. Nature 2008, 453:948-951.
199. Shumaker D.K., Dechat T., Kohlmaier A., et al. Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc Natl Acad Sci U S A 2006, 103:8703-8708.
200. Dolnik A., Engelmann J.C., Scharfenberger-Schmeer M., et al. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood 2012, 120:e83-e92.
201. Kihara R., Nagata Y., Kiyoi H., et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014, 28:1586-1595.
202. Thol F., Bollin R., Gehlhaar M., et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood 2014, 123:914-920.
203. Welch J.S., Ley T.J., Link D.C., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150:264-278.
204. Leeke B., Marsman J., O'Sullivan J.M., Horsfield J.A. Cohesin mutations in myeloid malignancies: underlying mechanisms. Exp Hematol Oncol 2014, 3:13.
205. Thota S., Viny A.D., Makishima H., et al. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood 2014, 124:1790-1798.
206. Shlush L.I., Zandi S., Mitchell A., et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014, 506:328-333.